| 摘要 |
Inhibitors of bone calcium resorption are administered to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating non-calcium related diseases such as cancer, psoriasis, and autoimmune disease without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-kappaB ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-kappaB gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1alpha,25-dihydroxyvitamin D<SUB>3 </SUB>(1,25-(OH)<SUB>2</SUB>D<SUB>3</SUB>), its analogs, prodrugs, or mimetics can be utilized with minimal risk to a patient. Specifically, alendronate is shown to block the bone calcium mobilization activity of both 1,25-(OH)<SUB>2</SUB>D<SUB>3 </SUB>and its very potent analog, 2-methylene -19-nor-(20S)-1alpha,25-dihydroxyvitamin D<SUB>3. </SUB> |
